News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
29-Oct-2009 - The new biological medicine Ilaris® (canakinumab) has been approved in the European Union (EU) to treat adults and children as young as four years old with cryopyrin-associated periodic syndrome (CAPS), a rare life-long auto-inflammatory disease with debilitating symptoms and few treatment ...
29-Oct-2009 - Amorfix Life Sciences announced it has detected prions in blood from non-human primates that were orally-infected with BSE and developed a primate version of vCJD. "Amorfix was able to obtain only a limited number of these very rare primate samples. Considering the small number of samples ...
28-Oct-2009 - ThromboGenics NV and co-development partner BioInvent International announced that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule. TB-402 is a long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following ...
28-Oct-2009 - CryoLife, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. BioFoam will be used to help seal liver ...
27-Oct-2009 - ExonHit announced that the United States Patent and Trademark Office notified the Company of its intent to issue a Re-examination Certificate in connection with ExonHit’s US Patent n° 6,881,571 directed to the use of its SpliceArray™ technology. The validity of this patent had been challenged ...
27-Oct-2009 - GlaxoSmithKline (GSK) and Genmab A/S announced the accelerated approval of ArzerraTM (ofatumumab) from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. "The approval of Arzerra brings an important ...
27-Oct-2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic ...
26-Oct-2009 - Movetis announced that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor (prucalopride – a 1mg and 2mg once a day oral tablet) for the symptomatic treatment of chronic constipation (CC) in women in whom laxatives fail to provide adequate ...
23-Oct-2009 - Crucell N.V. announced that preliminary results of the Phase I study of its HIV vaccine were presented at La Conférence AIDS Vaccine 2009 in Paris, France. The presentation was given by Dr Dan H. Barouch, MD, PhD, Associate Professor of Medicine, Division of Vaccine Research, Department of ...
22-Oct-2009 - New Phase II results show that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or 'flares' in patients with hard-to-treat gout, one of the most painful forms of arthritis. The ...
© 1997-2024 LUMITOS AG, All rights reserved